

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 4, 2019**

**Hepion Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**001-36856**  
(Commission  
File Number)

**46-2783806**  
IRS Employer  
Identification No.)

**399 Thornall Street, First Floor  
Edison, NJ 08837**  
(Address of principal executive offices)

Registrant's telephone number, including area code: **(732) 902-4000**

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock	HEPA	Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01 Other Events**

On September 4, 2019, Hepion Pharmaceuticals, Inc. (the "Company") issued a press release announcing that management will present an update on the Company's business at the H. C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019 at 4:15 p.m. Eastern Time in New York, NY. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

99.1 [Hepion Pharmaceuticals, Inc. Press Release dated September 4, 2019](#)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 4, 2019

HEPION PHARMACEUTICALS, INC.

By: /s/ Robert Foster  
Robert Foster  
Chief Executive Officer



**Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference**

**EDISON, N.J., September 4, 2019** - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that management will present an update on the Company’s business at the H. C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019 at 4:15 p.m. Eastern Time in New York, NY.

The presentation will be broadcast live and archived on the Company’s website at [www.hepionpharma.com](http://www.hepionpharma.com) under “Events” in the Investors section.

**About Hepion Pharmaceuticals**

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431’s potent inhibition of cyclophilin enzymes, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease.

For further information, please contact:

Stephen Kilmer  
Hepion Pharmaceuticals Investor Relations  
Direct: (646) 274-3580  
[skilmer@hepionpharma.com](mailto:skilmer@hepionpharma.com)

---